Showing posts with label A.P. Pharma. Show all posts
Showing posts with label A.P. Pharma. Show all posts
Tuesday, July 31, 2012
A.P. Pharma adds Robert Rosen to board
A.P. Pharma Inc. said Tuesday it has added Robert Rosen to its board of directors. The Redwood City-based (OTCBB:APPA.OB) specialty pharmaceutical company said Rosen is managing partner of Scotia Nordic LLC. Before that he was global head of oncology at Bayer HealthCare.
Thursday, July 14, 2011
Transcent Medical's $51M leads life science funding roundup
Transcend Medical leads a list of recent financing action by Bay Area life sciences companies.
Transcend closed a $51 million Series B round, including a previously announced $35 million.
Transcend closed a $51 million Series B round, including a previously announced $35 million.
Monday, April 25, 2011
A.P. Pharma raises $4.5M, installs new executive team
A.P. Pharma Inc. has raised up to $4.5 million in convertible notes and named a new executive team, the company said Monday.
The Redwood City specialty pharmaceutical company secured the funding from investors including Tang Capital Partners LP.
The Redwood City specialty pharmaceutical company secured the funding from investors including Tang Capital Partners LP.
Monday, March 28, 2011
A.P. Pharma seeks bridge loan, will move to OTC bulletin board
A.P. Pharma Inc. said Monday it will not dispute a Nasdaq delist notice and expects to transfer to the Over the Counter Bulletin Board.
Redwood City-based A.P. Pharma (NASDAQ:APPA) said it is also in negotiations for a bridge loan to fund operations until additional longer-term financing is secured.
Redwood City-based A.P. Pharma (NASDAQ:APPA) said it is also in negotiations for a bridge loan to fund operations until additional longer-term financing is secured.
Subscribe to:
Comments (Atom)